<DOC>
	<DOCNO>NCT03060551</DOCNO>
	<brief_summary>This study outline safety autologous SVF cell injection hand patient SSc . Preliminary assessment 6 month suggest potential efficacy need confirmation randomise placebo-controlled trial large population</brief_summary>
	<brief_title>Injection Autologous Adipose-derived Stromal Vascular Fraction Finger Systemic Sclerosis Patients</brief_title>
	<detailed_description>In patient systemic sclerosis ( scleroderma , SSc ) , impaired hand function greatly contribute disability reduce quality life , insufficiently relive currently available therapy . Adipose tissue-derived stromal vascular fraction ( SVF ) increasingly recognize easily accessible source regenerative cell therapeutic potential ischaemic autoimmune disease . The investigator aim measure first time safety , tolerability , potential efficacy autologous SVF cell local injection patient SSc hand disability .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>age 18 year old Cochin Hand Function Scale ( CHFS ) &gt; 20/90 new vasodilator immunosuppressive therapy SSc 3 month prior enrolment new vasodilator immunosuppressive therapy SSc 6month followup clinical radiological sign digital infection positive status HIV positive status hepatitis B C positive status human Tcell leukemia virus 12 positive status syphilis pregnancy BMI le 17kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>